Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type1 Diabetes Clear all
Completed Not applicable Interventional Results available

Pramlintide in Adolescents With Type 1 Diabetes

NCT00842075
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
pramlintide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 23, 2026, 3:26 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

NCT00700622
View directory record Official record
Conditions
Diabetes, Type 1
Interventions
Technosphere Insulin, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 23, 2026, 3:26 PM EDT
Recruiting No phase listed Observational

Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes

NCT05849753
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Child, Delivery of Health Care, Equipment and Supplies
Interventions
Advanced artificial pancreas closed-loop technology
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Jacksonville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Not applicable Interventional Results available

Assessment of an Automatic Closed-loop Insulin Delivery System

NCT02366767
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Automatic closed-loop insulin delivery, Control
Device
Lead sponsor
Stanford University
Other
Eligibility
14 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Angelus Oaks, California • Mountain View, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 23, 2026, 3:26 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Islet After Kidney Transplant for Type 1 Diabetes

NCT00784966
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
etanercept
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.

NCT00424437
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled human insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
29
States / cities
Burlingame, California • Irvine, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2007 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients

NCT02099981
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Aminoguanidine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 23, 2026, 3:26 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 23, 2026, 3:26 PM EDT
No Longer Available No phase listed Expanded access

Islet Transplant for Type 1 or Surgical Diabetes

NCT01606475
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
Interventions
Allogeneic islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting

NCT01638299
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypo-Hyper Minimizer (HHM) System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer

NCT00069628
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
GlucoWatch® G2™ Biographer (GW2B), Continuous Glucose Monitoring System (CGMS)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
6
States / cities
Stanford, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Not applicable Interventional Results available

Adaptive Biobehavioral Control (ABC) in a Closed-Loop System

NCT05610111
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CLC + BAM, CLC + ABC
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

NCT02735044
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 23, 2026, 3:26 PM EDT
Active, not recruiting Phase 2 Interventional

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents

NCT00097071
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 18 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 23, 2026, 3:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

NCT01900834
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
14 Years to 40 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 4 Interventional

Comparison of Glycemic Control Achieved With 2 Different Needles

NCT00572052
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
NovoFine® needle 6 mm, Ultra-Fine needle 12.7 mm
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Walnut Creek, California • Berlin, New Jersey • Lawrenceville, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 4 Interventional

Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus

NCT04030091
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
3 hours humulin R 100 IU/mL PIT, 2 hours humulin R 100 IU/mL PIT
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

NCT01997411
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Nasal Glucagon, Intramuscular Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
4 Years to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 23, 2026, 3:26 PM EDT
Terminated Not applicable Interventional Results available

Continuous Glucose Monitoring Initiation at Hospital Discharge

NCT04854135
View directory record Official record
Conditions
Type 1 Diabetes, Type2 Diabetes, Hyperglycemia, Hypoglycemia, Hypoglycemia Unawareness
Interventions
CGM4Home
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 23, 2026, 3:26 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation and Comparison of Noninvasive Blood Glucose Concentrations

NCT01745900
View directory record Official record
Conditions
Insulin Dependent Diabetes, Non Insulin Dependent Diabetes, Gestational Diabetes
Interventions
Not listed
Lead sponsor
VeraLight, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 23, 2026, 3:26 PM EDT
Not yet recruiting Phase 2 Interventional

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

NCT07616206
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Cadisegliatin 800 mg QD, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 3:26 PM EDT
Recruiting Not applicable Interventional

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

NCT07287943
View directory record Official record
Conditions
Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I
Interventions
Medtronic 780G AID
Device
Lead sponsor
Viral N. Shah
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 23, 2026, 3:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia

NCT01919385
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Predictive Low Glucose Minimizer
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Sep 23, 2026, 3:26 PM EDT